Acadian Asset Management’s Terns Pharmaceuticals TERN Stock Holding History

Acadian Asset Management’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-98	Closed	-$5K	–	2235
2026 Q1	$5K	Sell	98 -188,927	-100%	-$7.76M	﹤0.01%	1989
2025 Q4	$7.63M	Buy	+189,025	New	+$4.37M	0.01%	542
2024 Q4	–	Sell	-19,436	Closed	-$162K	–	2153
2024 Q3	$162K	Buy	+19,436	New	+$160K	﹤0.01%	1439
2023 Q1	–	Sell	-22,599	Closed	-$229K	–	1975
2022 Q4	$229K	Buy	22,599 +9,972	+79%	+$66.4K	﹤0.01%	1247
2022 Q3	$74K	Hold	12,627	–	–	﹤0.01%	1431
2022 Q2	$31K	Buy	+12,627	New	+$25.2K	﹤0.01%	1567

Other funds holding TERN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Acadian Asset Management's TERN Position: Q2 2026 in Review

Acadian Asset Management sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 98 shares — an estimated $5K sold.

Acadian Asset Management first reported a position in TERN in Q2 2022 and held it in 6 quarters. The position peaked at $7.63M in Q4 2025. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

Acadian Asset Management reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Acadian Asset Management sold 98 Terns Pharmaceuticals shares in Q2 2026, an estimated $5K.
Acadian Asset Management first reported a position in Terns Pharmaceuticals in Q2 2022 and held it in 6 quarters.
Acadian Asset Management's Terns Pharmaceuticals position peaked at $7.63M in Q4 2025.
1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.